We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

59 hedge funds and large institutions have $46.1M invested in Actinium Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 9

117% more capital invested

Capital invested by funds: $21.2M → $46.1M (+$24.9M)

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

6.2% more ownership

Funds ownership: 11.42% → 17.62% (+6.2%)

5% more funds holding

Funds holding: 56 → 59 (+3)

17% less call options, than puts

Call options by funds: $3.46M | Put options by funds: $4.18M

Holders
59
Holders Change
+3
Holders Change %
+5.36%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
25
Reduced
9
Closed
8
Calls
$3.46M
Puts
$4.18M
Net Calls
-$712K
Net Calls Change
-$1.93M

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.43M
2
BlackRock
BlackRock
New York
+$2.33M
3
Two Sigma Investments
Two Sigma Investments
New York
+$2M
4
EI
EAM Investors
California
+$2M
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$1.98M

Top Sellers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
-$713K
2
JGC
J. Goldman & Co
New York
-$696K
3
Simplex Trading
Simplex Trading
Illinois
-$347K
4
Franklin Resources
Franklin Resources
California
-$153K
5
William Blair & Company
William Blair & Company
Illinois
-$148K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$11.9M +$488K +48,104 +5%
BlackRock
2
BlackRock
New York
$5.14M +$2.33M +229,548 +91%
D.E. Shaw & Co
3
D.E. Shaw & Co
New York
$2.95M +$2.43M +239,196 +631%
Two Sigma Advisers
4
Two Sigma Advisers
New York
$2.55M +$1.98M +195,100 +441%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2.47M +$178K +17,520 +8%
Two Sigma Investments
6
Two Sigma Investments
New York
$2.27M +$2M +197,494 +1,248%
EI
7
EAM Investors
California
$2.1M +$2M +197,021 New
Renaissance Technologies
8
Renaissance Technologies
New York
$1.7M +$825K +81,300 +104%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$1.59M +$1.39M +137,316 +1,131%
Citadel Advisors
10
Citadel Advisors
Florida
$1.29M +$815K +80,314 +195%
EGI
11
EAM Global Investors
California
$1.23M +$1.17M +115,387 New
William Blair & Company
12
William Blair & Company
Illinois
$952K -$148K -14,566 -14%
BCM
13
Bridgeway Capital Management
Texas
$947K – – –
State Street
14
State Street
Massachusetts
$941K +$133K +13,100 +17%
JGC
15
J. Goldman & Co
New York
$853K -$696K -68,630 -46%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$628K – – –
Millennium Management
17
Millennium Management
New York
$573K +$47K +4,632 +9%
Citigroup
18
Citigroup
New York
$523K +$421K +41,523 +544%
ECM
19
ExodusPoint Capital Management
New York
$494K +$470K +46,347 New
ECM
20
Endurant Capital Management
California
$486K +$463K +45,612 New
Northern Trust
21
Northern Trust
Illinois
$477K +$56.3K +5,551 +14%
Morgan Stanley
22
Morgan Stanley
New York
$431K -$98.4K -9,699 -19%
CSS
23
Cubist Systematic Strategies
Connecticut
$365K +$348K +34,298 New
VF
24
Virtu Financial
New York
$286K +$145K +14,264 +113%
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$273K +$101K +9,930 +63%
1
2 3

ATNM Hedge Fund Activity: Q4 2022 in Review

59 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2022, worth a combined $46.1M — up 117% from $21.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ATNM positions and 8 closed out — a net gain of 3 holders — while 25 added to existing stakes and 9 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $2.43M. The largest seller was Group One Trading, cutting an estimated $713K.

  • 59 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2022, up from 56 in Q3 2022.
  • Funds reported $46.1M of Actinium Pharmaceuticals stock for Q4 2022, up 117% quarter-over-quarter.
  • 11 funds opened new Actinium Pharmaceuticals positions in Q4 2022 and 8 closed out, a net change of +3 holders.
  • The largest Actinium Pharmaceuticals buyer in Q4 2022 was D.E. Shaw & Co, an estimated $2.43M added.
  • The largest Actinium Pharmaceuticals seller in Q4 2022 was Group One Trading, an estimated $713K sold.

Based on aggregated 13F filings for Q4 2022.